Pulse Biosciences, Inc. has appointed Paul A. LaViolette as its Chief Executive Officer. LaViolette, who is currently the Co-Chairman of the Board, brings significant experience as a large-scale operator at global healthcare corporations and as a leader to a diverse group of innovative medical technology startups. He has also served in various executive capacities at Boston Scientific Corporation for 15 years and has experience scaling global franchises across multiple clinical specialties.
LaViolette's appointment comes as the company continues the development of its nano-PFA Cardiac Surgical System and nano-PFA 360° Cardiac Catheter through first-in-human feasibility studies in Europe. Additionally, the company is conducting a pilot program with its FDA-cleared nsPFA Percutaneous Electrode Systems at select sites in the United States.
In accordance with Nasdaq Listing Rule 5635(c)(4), the company has granted inducement awards of options to purchase a collective total of up to 138,800 shares of common stock to eleven new employees of the Company. The options have a ten-year term and an exercise price of $18.55 per share. These options are subject to vesting in equal annual installments over a four-year period, except for the award to a newly hired company vice president for 65,000 option shares, whose grant will vest 50% over the same four-year period and 50% upon the achievement of market capitalization milestones for the company ranging from $1 billion to $3 billion.
Pulse Biosciences is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
The company is presenting at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco and the 30th Annual AF Symposium 2025 meeting in Boston where Nano-PFA technology and the 360 Catheter will be featured in a late breaking science session and a live case transmission.
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation and is now headquartered in Miami, Florida, maintaining its office in Hayward, California. Today the company's shares have moved -3.2% to a price of $17.44. For more information, read the company's full 8-K submission here.
